Autolus Therapeutics plc (FRA:6A3A)
Germany · Delayed Price · Currency is EUR 2.060
+0.070 (3.52%)
At close: Aug 26, 2026
Autolus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 117.39 | 75.39 | 10.12 | 1.7 | 6.36 | 2.33 | |
Revenue Growth | 292.16% | 644.94% | 496.00% | -73.30% | 172.96% | 35.86% |
Cost of Revenue | 204.97 | 207.38 | 141.02 | 122.31 | 117.35 | 110.84 |
Gross Profit | -87.58 | -132 | -130.9 | -120.62 | -110.99 | -108.51 |
Selling, General & Admin | 159.51 | 138.2 | 110.11 | 54.91 | 31.9 | 31.87 |
Operating Expenses | 159.51 | 138.2 | 110.11 | 54.91 | 31.9 | 31.87 |
Operating Income | -247.09 | -270.2 | -241.01 | -175.53 | -142.89 | -140.37 |
Interest Expense | -45.15 | -42.37 | -39.94 | -45.07 | -8.91 | -1.11 |
Interest & Investment Income | 11.96 | 18.98 | 32.36 | 13.51 | 1.71 | 0.26 |
Currency Exchange Gain (Loss) | -2.72 | 2.16 | -0.99 | 2.64 | 1.8 | -2.3 |
Other Non Operating Income (Expenses) | 3.88 | 6.21 | 30.86 | 0.22 | 0.34 | 0.16 |
EBT Excluding Unusual Items | -279.13 | -285.21 | -218.72 | -204.23 | -147.95 | -143.36 |
Gain (Loss) on Sale of Assets | - | - | - | -3.79 | -0.52 | -0.68 |
Asset Writedown | -0.35 | -0.35 | -0.41 | -0.38 | - | - |
Other Unusual Items | - | - | - | - | -0.1 | 2 |
Pretax Income | -279.48 | -285.56 | -219.13 | -208.4 | -148.57 | -142.04 |
Income Tax Expense | 0.68 | 1.97 | 1.53 | -0.02 | 0.27 | 0.06 |
Net Income | -280.16 | -287.53 | -220.66 | -208.38 | -148.84 | -142.1 |
Net Income to Common | -280.16 | -287.53 | -220.66 | -208.38 | -148.84 | -142.1 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 266 | 266 | 255 | 174 | 95 | 72 |
Shares Outstanding (Diluted) | 266 | 266 | 255 | 174 | 95 | 72 |
Shares Change | 2.10% | 4.30% | 46.69% | 83.11% | 31.78% | 39.81% |
EPS (Basic) | -1.05 | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
EPS (Diluted) | -1.05 | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -232.73 | -302.61 | -228.35 | -156.57 | -123.15 | -126.72 |
Free Cash Flow Per Share | -0.87 | -1.14 | -0.90 | -0.90 | -1.30 | -1.76 |
Gross Margin | -74.60% | -175.09% | - | - | - | - |
Operating Margin | -210.49% | -358.41% | -2381.54% | -10337.34% | -2246.74% | -6024.64% |
Profit Margin | -238.65% | -381.40% | -2180.45% | -12272.26% | -2340.24% | -6098.54% |
Free Cash Flow Margin | -198.25% | -401.41% | -2256.38% | -9221.02% | -1936.31% | -5438.54% |
EBITDA | -236.57 | -260.38 | -233.3 | -168.96 | -135.54 | -132.01 |
D&A For EBITDA | 10.52 | 9.81 | 7.72 | 6.57 | 7.36 | 8.37 |
EBIT | -247.09 | -270.2 | -241.01 | -175.53 | -142.89 | -140.37 |
Revenue as Reported | 117.39 | 75.39 | 10.12 | 1.7 | - | - |